Li Kang Biomedical Co Ltd (6242) - Net Assets
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has net assets worth NT$871.24 Million TWD (≈ $27.45 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.09 Billion ≈ $34.44 Million USD) and total liabilities (NT$221.82 Million ≈ $6.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Li Kang Biomedical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$871.24 Million |
| % of Total Assets | 79.71% |
| Annual Growth Rate | 4.08% |
| 5-Year Change | 77.08% |
| 10-Year Change | 155.64% |
| Growth Volatility | 173.46 |
Li Kang Biomedical Co Ltd - Net Assets Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Li Kang Biomedical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual net assets of Li Kang Biomedical Co Ltd from 2002 to 2025. For live valuation and market cap data, see Li Kang Biomedical Co Ltd (6242) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$871.24 Million ≈ $27.45 Million |
+1.82% |
| 2024-12-31 | NT$855.68 Million ≈ $26.96 Million |
+35.82% |
| 2023-12-31 | NT$630.03 Million ≈ $19.85 Million |
+10.51% |
| 2022-12-31 | NT$570.14 Million ≈ $17.96 Million |
+15.88% |
| 2021-12-31 | NT$492.00 Million ≈ $15.50 Million |
-3.21% |
| 2020-12-31 | NT$508.30 Million ≈ $16.01 Million |
+5.14% |
| 2019-12-31 | NT$483.44 Million ≈ $15.23 Million |
+3.54% |
| 2018-12-31 | NT$466.92 Million ≈ $14.71 Million |
+4.77% |
| 2017-12-31 | NT$445.68 Million ≈ $14.04 Million |
+30.77% |
| 2016-12-31 | NT$340.80 Million ≈ $10.74 Million |
+21.59% |
| 2015-12-31 | NT$280.29 Million ≈ $8.83 Million |
+23.24% |
| 2014-12-31 | NT$227.44 Million ≈ $7.17 Million |
+836.40% |
| 2013-12-31 | NT$24.29 Million ≈ $765.24K |
-71.46% |
| 2012-12-31 | NT$85.12 Million ≈ $2.68 Million |
-31.04% |
| 2011-12-31 | NT$123.43 Million ≈ $3.89 Million |
+18.33% |
| 2010-12-31 | NT$104.31 Million ≈ $3.29 Million |
-18.81% |
| 2009-12-31 | NT$128.49 Million ≈ $4.05 Million |
-32.84% |
| 2008-12-31 | NT$191.32 Million ≈ $6.03 Million |
-53.51% |
| 2007-12-31 | NT$411.54 Million ≈ $12.97 Million |
+90.57% |
| 2006-12-31 | NT$215.94 Million ≈ $6.80 Million |
-3.36% |
| 2005-12-31 | NT$223.45 Million ≈ $7.04 Million |
-30.91% |
| 2004-12-31 | NT$323.44 Million ≈ $10.19 Million |
-4.33% |
| 2003-12-31 | NT$338.06 Million ≈ $10.65 Million |
-2.76% |
| 2002-12-31 | NT$347.64 Million ≈ $10.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Li Kang Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 459.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$265.29 Million | 30.45% |
| Other Components | NT$605.95 Million | 69.55% |
| Total Equity | NT$871.24 Million | 100.00% |
Li Kang Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HS Valve Co. Ltd
KQ:039610
|
$34.50 Million |
|
Unite Group PLC
LSE:UTG
|
$34.52 Million |
|
Legacy Iron Ore Ltd
AU:LCY
|
$34.54 Million |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
$34.55 Million |
|
Corem Property Group AB (publ)
ST:CORE-A
|
$34.46 Million |
|
CORESTEM Inc
KQ:166480
|
$34.44 Million |
|
Coventry Group Ltd
AU:CYG
|
$34.44 Million |
|
Total Soft Bank Ltd
KQ:045340
|
$34.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Li Kang Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 855,683,000 to 871,244,000, a change of 15,561,000 (1.8%).
- Net income of 83,824,000 contributed positively to equity growth.
- Dividend payments of 63,613,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$83.82 Million | +9.62% |
| Dividends Paid | NT$63.61 Million | -7.3% |
| Other Changes | NT$-4.65 Million | -0.53% |
| Total Change | NT$- | 1.82% |
Book Value vs Market Value Analysis
This analysis compares Li Kang Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.71x to 1.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$20.08 | NT$34.40 | x |
| 2018-12-31 | NT$21.03 | NT$34.40 | x |
| 2019-12-31 | NT$17.32 | NT$34.40 | x |
| 2020-12-31 | NT$18.21 | NT$34.40 | x |
| 2021-12-31 | NT$17.67 | NT$34.40 | x |
| 2022-12-31 | NT$20.45 | NT$34.40 | x |
| 2023-12-31 | NT$22.60 | NT$34.40 | x |
| 2024-12-31 | NT$26.90 | NT$34.40 | x |
| 2025-12-31 | NT$27.39 | NT$34.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Li Kang Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.62%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.23%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.25x
- Recent ROE (9.62%) is below the historical average (15.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 5.60% | 2.07% | 1.23x | 2.20x | NT$-15.31 Million |
| 2015 | 18.86% | 11.60% | 0.87x | 1.88x | NT$24.82 Million |
| 2016 | 18.05% | 13.65% | 0.81x | 1.63x | NT$27.43 Million |
| 2017 | 30.01% | 26.97% | 0.83x | 1.34x | NT$89.17 Million |
| 2018 | 16.43% | 15.48% | 0.81x | 1.31x | NT$30.05 Million |
| 2019 | 14.90% | 14.90% | 0.77x | 1.30x | NT$23.67 Million |
| 2020 | 13.63% | 15.17% | 0.71x | 1.27x | NT$18.44 Million |
| 2021 | 10.45% | 13.29% | 0.63x | 1.25x | NT$2.24 Million |
| 2022 | 19.66% | 16.38% | 0.99x | 1.21x | NT$55.08 Million |
| 2023 | 17.62% | 17.64% | 0.76x | 1.31x | NT$47.99 Million |
| 2024 | 9.00% | 13.62% | 0.55x | 1.21x | NT$-8.54 Million |
| 2025 | 9.62% | 14.23% | 0.54x | 1.25x | NT$-3.30 Million |
Industry Comparison
This section compares Li Kang Biomedical Co Ltd's net assets metrics with peer companies in the Travel Services industry.
Industry Context
- Industry: Travel Services
- Average net assets among peers: $1,297,115,000
- Average return on equity (ROE) among peers: 5.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Li Kang Biomedical Co Ltd (6242) | NT$871.24 Million | 5.60% | 0.25x | $34.47 Million |
| Lion Travel Service Co Ltd (2731) | $2.26 Billion | 9.69% | 2.88x | $432.00 Million |
| Richmond International Travel & Tours Co Ltd (2743) | $469.99 Million | -11.16% | 0.61x | $85.99 Million |
| Phoenix Tours International Inc (5706) | $1.16 Billion | 17.18% | 1.16x | $117.44 Million |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more